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The September issue of the European Respiratory Review presents two viewpoints on the
regulation of medical devices http://ow.ly/mX5E300p3yw
In our previous issue, we introduced two new sections to the European Respiratory Review: one entitled
“Frontiers in Clinical Practice”, with a paper by JENY et al. [1] brilliantly illustrating certain critical aspects
of sarcoidosis with some clinical examples, and a second named “Mini-Review: Health and Politics”, in
which the World Health Organization representative to the European Union, Roberto Bertollini, provided
readers with a fascinating snapshot of the measures in place across Europe to combat smoking [2].
The current issue casts light on an on-going debate on the process for approving medical devices,
describing experiences in the field of cardiology. Two equally valid viewpoints are put forward: one is
presented in a Health and Politics Mini-Review by Rosanna Tarricone [3], an economist and the Director
of CERGAS, the healthcare research centre at Milan’s famous Bocconi University in Italy, while the other
is presented in an accompanying editorial [4] by Maria Frigerio, an extensively experienced clinical
cardiologist who is the Director of the Heart Transplant and Heart Failure Programme at the De Gasperis
Cardiology Centre, Milan, one of the Europe’s leading cardiological and heart surgery facilities.
Some might wonder why a respiratory review journal such as ours should be turning its attention to
cardiological medical devices. The answer can be found in the editorial with which I made my debut as
the Chief Editor of the European Respiratory Review (ERR): our intention is to open the review up to
specialists from a wide range of fields, strenuously emphasise the interdisciplinary nature of respiratory
medicine and modern medicine in general and, just as importantly, tackle topics of common interest to
our readers, such as healthcare organisation and policies [5].
The branches of cardiology and cardiac surgery are the closest to pulmonology where medical devices have
been most widely used and adopted in recent years. Therefore, we trust that ERR readers will appreciate
exploring the latest developments in a field that has major crossover with our specific branch of medicine
as well.
The mini-review by TARRICONE et al. [3] offers an interesting perspective on how “real world” data can be used
for building reliable evidence (and, consequently, performing health technology assessments) in device-based
therapies, when evidence from comparative, randomised studies are unavailable, difficult to obtain or
inconclusive. This analysis, based on the example of the MitraClip device (Abbott Vascular, Santa Clara, CA,
USA), leaves some significant unanswered questions: is a new technology good just because one regulator
allowed it to be used, while another did not? Are Austrian and UK patients deprived of a valuable option due
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only to excessively rigorous methodological, theoretical issues, or are Spanish and Italian patients exposed to
the uncertainties of an experimental therapy that has been (perhaps prematurely) included in the healthcare
system basket? The accompanying editorial by FRIGERIO [4] seems to admit that, given the current regulatory
environment, no incontrovertible answers are available to clinicians, patients or payers. However, some
optimism may derive from several cases pointing to the successful use of “classic” randomised controlled trial
methodology in providing sound evidence for supporting or denying the value of device-based therapies.
Moreover, the author suggests shifting the “burden of proof” from the post-market to the pre-market setting,
possibly with the contribution of public research funding, in order to guarantee a timely and reliable
evaluation of innovative therapies, at the same time protecting patients and the community at large from the
risks and costs associated with treatments with unproven benefits. I hope that ERR readers will take advantage
of this cardiological experience, and keep an open-minded but critical attitude when designing, conducting
and evaluating research on device-based therapy for respiratory conditions.
References
1 Jeny F, Bouvry D, Freynet O, et al. Management of sarcoidosis in clinical practice. Eur Respir Rev 2016; 25:
141–150.
2 Bertollini R, Ribeiro S, Mauer-Stender K, et al. Tobacco control in Europe: a policy review. Eur Respir Rev 2016; 25:
151–157.
3 Tarricone R, Boscolo PA, Armeni P. What type of clinical evidence is needed to assess medical devices? Eur Respir
Rev 2016; 25: 259–265.
4 Frigerio M. Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
Eur Respir Rev 2016; 25; 223–226.
5 Harari S. Why we should care about ultra-rare disease. Eur Respir Rev 2016; 25; 101–103.
222 DOI: 10.1183/16000617.0045-2016
ADDING NEW PERSPECTIVES | S. HARARI
